

Wilsons Drug & Device Conference

Healing. Redefined.

October 26, 2023

Disclaimer



This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. PolyNovo Limited makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. PolyNovo and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, or contained in or derived from, or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of PolyNovo. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by PolyNovo or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

NovoSorb®

Genius technology

Underserved market

Capital efficient **Growth** and **Scaling**



Innovation driven out of frustration with the Existing Standard of Care

2002

CSIRO

2004


Australian survivors were repatriated to major Burns units for treatment. Large, delayed and colonized wounds required dermal substitutes, but the existing SOC carried risk of infection and rejection. Prof. John Greenwood (Burns Unit, Royal Adelaide Hospital) sought a synthetic alternative

Bali Bombing kills 202 and critically injures 209.

The CSIRO developed a family of polymers -- synthetic material that could safely biodegrade and be metabolised by the human body -- for use in implantable medical devices. CSIRO/PolyNovo collaboration with Prof. John Greenwood results in development of NovoSorb® BTM

2008: PolyNovo acquired by a ASX listed company; pre-clinical studies and factory established in Port Melbourne.






NovoSorb[®]: Simple. Elegant. Transformative


Macro to Micro wounds:

NovoSorb BTM's matrix organizes a large wound (macrowound) into a series of interconnected small wounds (microwounds). The body easily heals small wounds, promoting organized, regenerative healing.

- Biocompatible
- Resorbable


Optimized Regenerative Healing





- 100% synthetic, maintains integrity over time and resistant to shear forces.
- · Clinically shown to be robust in presence of infection.
- Flexible, allowing clinicians to skin graft at their convenience, in stages or all at once.
- · Virtually unlimited in its supply or consistency unlike biologics.
- Used by a variety of Surgeons including Plastic, Reconstructive, Trauma and General

Minimizes scarring. Restores form and function.




Robust IP Portfolio

PolyNovo has obtained IP Protection for its 10 Patent families(incl. 61 patents & 28 patent applications) in a broad range of countries including commercial destinations. These incl. protection for compositions of matter, as well as their general & specific medical use in applications including stents, orthopedic repair, burns & wound repair, hernia, diabetic ulcer & breast reconstruction. The patents and applications are fully owned by PolyNovo, providing protection for company's technologies until as far out as **2038**.

Disciplined Execution


Yielding Strong Business Results and Redefining the Standard of Care




- Market entry options being evaluated
- * Seeking alliances

US FDA has cleared NovoSorb BTM wound dressing for management of wounds including; partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic and vascular ulcers, surgical wounds (donor sites/grafts, post Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second degree burns and skin tears) and draining wounds

Where are we today?




NovoSorb® Will Disrupt Several Attractive Addressable Markets



Source : Global Data, Zion reports, 2021, WHO, Government sources M - 000; MM - 000,000; B - Billion

Global Strategy on a Page:

Focused on Burns & Trauma – Working with alliances in adjacencies



An Exciting Future,

Uniquely situated to drive Global leadership and impact


- Genius Technology: Product to Procedure & Platform
- Underserved market : From 800m to 7.2B people
- Committed to Capital Efficient Growth & Scaling

Purpose driven, Engaged organization

Building Global Organization, Processes and Technology to enable scale

Next Generation Reconstructive Option

- Customers helping us drive adoption curve and market development
- Building sustainable **partnerships** will help **amplify impact** beyond our core focus areas





Thank you